Advice
Following a full submission.
Rasagiline (Azilect) is not recommended for use within NHS Scotland for the treatment of idiopathic Parkinson’s disease as adjunct therapy (with levodopa) in patients with end of dose fluctuations.
Rasagiline reduces off-time in patients with Parkinson’s disease and end of dose fluctuations on levodopa, similar to reductions shown with the less effective of two currently marketed catechol-O-methyl transferase inhibitors. However, there are no comparative data with the other monoamine oxidase-B inhibitor, which is less expensive. The economic case has not been demonstrated.
Download detailed advice48KB (PDF)
Medicine details
- Medicine name:
- Rasagiline 1mg tablet (Azilect®)
- SMC ID:
- 255/06
- Indication:
- Idiopathic Parkinsons disease as adjunct therapy
- Pharmaceutical company
- Lundbeck Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 13 March 2006